Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto

Robert S. Remis†, Juan Liu†, Mona R. Loutfy¹,²,³, Wangari Tharao⁴, Anuradha Rebbapragada⁵,⁶, Sanja Huibner⁷, Maya Kesler⁸, Roberta Halpenny⁹, Troy Grennan³,⁸, Jason Brunetta³, Graham Smith³, Tatjana Reko³, Rupert Kaul⁷,*

¹ Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada, ² Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada, ³ Maple Leaf Medical Clinic, Toronto, Ontario, Canada, ⁴ Women’s Health in Women’s Hands Community Health Centre, Toronto, Ontario, Canada, ⁵ Public Health Laboratory–Toronto Public Health Ontario, Toronto, Ontario, Canada, ⁶ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, ⁷ Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada, ⁸ Department of Medicine, McMaster University, Hamilton, Ontario, Canada

† Deceased.
* rupert.kaul@utoronto.ca

Abstract

Background
Hepatitis B (HBV), hepatitis C (HCV) and other sexually transmitted infections (STIs) have been associated with HIV transmission risk and disease progression among gay men and other men who have sex with men (MSM), but the frequency and distribution of STIs in this community in Canada has not been extensively studied.

Methods
We recruited MSM living with and without HIV from a large primary care clinic in Toronto. Participants completed a detailed socio-behavioural questionnaire using ACASI and provided blood for syphilis, HIV, HBV and HCV, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), and human cytomegalovirus (CMV) serology, urine for chlamydia and gonorrhea, and a self-collected anal swab for human papillomavirus (HPV) molecular diagnostics. Prevalences were expressed as a proportion and compared using chi-square.

Results
442 MSM were recruited, 294 living with HIV and 148 without. Active syphilis (11.0% vs. 3.4%), ever HBV (49.4% vs. 19.1%), HCV (10.4% vs. 3.4%), HSV-2 (55.9% vs. 38.2%), CMV (98.3% vs. 80.3%) and high-risk (HR) anal HPV (67.6% vs. 51.7%) infections were significantly more common in men living with HIV. Chlamydia and gonorrhea were infrequent in both groups. Regardless of HIV infection status, age and number of lifetime male
sexual partners were associated with HBV infection and lifetime injection drug use with HCV infection.

Conclusions
Syphilis and viral infections, including HBV, HCV, HSV-2, CMV, and HR-HPV, were common in this clinic-based population of MSM in Toronto and more frequent among MSM living with HIV. This argues for the implementation of routine screening, vaccine-based prevention, and education programs in this high-risk population.

Introduction
Despite significant advances in the care of those affected by the human immunodeficiency virus (HIV) over the last several decades, this infection remains a substantial public health challenge. In Canada, the HIV epidemic has disproportionately impacted several communities, specifically gay men, bisexual men, and other men who have sex with men (MSM), people who inject drugs (IDU), persons from HIV-endemic countries and Aboriginal people[1]. The estimated HIV prevalence in Canada in 2011 was 208.0 per 100,000 population, and nearly half (49.7%) of those living with HIV were MSM[1]. Furthermore, 15% of the approximately 108,000 MSM living in Ontario are estimated to be living with HIV[2]. This proportion is higher in the large urban centres, with the prevalence among Toronto MSM estimated to be 18%[2].

MSM and bisexual men are also at greater risk for other sexually transmitted infections (STIs) compared to heterosexual populations, including Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), human cytomegalovirus (CMV), and human papillomavirus (HPV)[3–8]. In addition to their direct clinical effects, these STIs may cause anogenital ulcers or mucosal inflammation, potentiating the transmission of HIV[9–15]. Furthermore, studies have found that HIV-infected MSM have a higher prevalence of co-infection with other STIs than HIV-negative MSM[5, 10, 16–18].

Hepatitis B virus (HBV), hepatitis C (HCV) and HIV are all blood-borne infections and share common routes of transmission, so co-infection by these pathogens is common[19]. While HIV increases the risk of HBV and HCV-related liver disease progression[20], the effect of HBV and HCV on HIV disease progression is unclear[21]. Nonetheless, there is evidence that the presence of HBV or HCV is independently associated with an increased risk of progression to AIDS and death[22–25]. HBV is transmitted through perinatal, percutaneous, or sexual contact with infectious biologic fluids. Canada is a region of low endemicity of HBV infection; about 5% of Canadians have had hepatitis B at some time in their lives, and 0.7–0.9% are chronically infected[26]. However, certain vulnerable populations are disproportionately affected, including MSM, Aboriginal peoples, street-involved youth, and people with current or prior history of incarceration. The most commonly identified risk factors are condomless sex and injection drug use (IDU)[26]. The estimated worldwide prevalence of HCV infection is 2.8%[27]. HCV is most efficiently spread through exposure to contaminated blood and blood products, particularly in persons with IDU[19]. Sexual transmission of HCV is inefficient and uncommon in the general population; however, it is becoming widely recognized as a growing public health issue among people living with HIV. Studies indicate that MSM who are living with HIV and who practice condomless sex are at increased risk for sexually acquired HCV[28–30].
The epidemiology of these co-infections among both HIV-positive and HIV-negative MSM is not well characterized in Canada. Additionally, MSM in Toronto are significantly affected by the HIV epidemic, with an estimated HIV prevalence of 18% and an annual incidence of 1% [2]. Therefore, data regarding the prevalence and correlates of these co-infections in HIV-infected and uninfected men will inform the local clinicians, public health staff and community organizations that provide screening, care and counseling to the MSM community in Toronto. We aimed to determine the prevalence and correlates of bacterial and viral STIs among MSM living with and without HIV in Toronto, Ontario.

Methods

Participants and recruitment

The study population consisted of MSM who were 18 years of age or older and living in Greater Toronto. Subjects were recruited from Maple Leaf Medical Clinic (MLMC) from September 2010 to June 2012. This clinic is located in downtown Toronto and predominantly serves a large MSM community with a high HIV prevalence. All participants provided informed written consent and the study protocol was approved by the HIV Research Ethics Board of the University of Toronto. The study utilized a non-random convenience, non-representative sampling approach with deliberate over-sampling of HIV-infected men. A list of randomly selected eligible clinic subjects was prepared, and those with a scheduled appointment were invited to speak to the Research Coordinator if interested in participation.

Study procedures

Participants completed a self-administered questionnaire using ACASI (Audio Computer Assisted Self-Interview), (Questionnaire Development System (QDS) Version 2.5, Nova Research Company, Bethesda, Maryland, USA) that included demographic information, sexual behaviour, history of STIs and other medical conditions.

Participants then provided a first-void urine specimen for Neisseria gonorrhoea and Chlamydia trachomatis molecular diagnostics, and self-collected an anal swab for HPV molecular diagnostics. Pre-test counselling for HIV and STI testing was performed, and blood collected for HIV, HSV-1, HSV-2, CMV, syphilis, HBV, and HCV serology.

Laboratory methods

Neisseria gonorrhoeae and Chlamydia trachomatis were tested in first-void urine specimens by nucleic acid amplification testing (NAAT) (ProbeTec™ ET Amplified DNA Assay, Becton Dickinson, Franklin Lakes, NJ, USA). The chemiluminescent microparticle immunoassay (CMIA) (Abbott Laboratories, Abbott Park, IL, USA) was used for syphilis screening and, if positive, the rapid plasma reagin (RPR, Pulse Diagnostic Inc, Burlington, ON) and confirmatory Treponema pallidum particle agglutination (TPPA) assay (Serodia TPPA, Fujirebo Inc) were performed. Participants were classified as having active syphilis infection if the CMIA, TPPA and RPR were all reactive, or as having treated syphilis if CMIA and TPPA were reactive and RPR was non-reactive. Participants self-reporting prior syphilis were classified as having treated syphilis, regardless of syphilis CMIA.

HIV testing was performed on serum by enzyme immunoassay (EIA; AxSYM HIV 1/2 gO, Abbott Diagnostics Division, Wiesbaden, Germany). If reactive, the EIA was repeated and confirmed at the Ontario Public Health Laboratory by combination antigen (Ag)/antibody (Ab) testing (Architect Ag/Ab Combo, Abbott Diagnostics, Abbott Park, IL, USA) and by Western blot. Serologic testing was also performed for herpes simplex, types 1 and 2 (Herpes Simplex
Virus ELISA IgG, Focus Diagnostics, Cypress, CA, USA); human cytomegalovirus (CMV; AxSYM CMV IgG; Abbott Diagnostics Division, Wiesbaden, Germany); HCV antibody (AxSYM HCV Version 3.0), with serologic confirmation of HCV-positive tests (Bio-Rad Monolisa anti-HCV Plus Version 2, Bio-Rad Laboratories, Montreal, Quebec); HBV surface antigen (AxSYM HbSAg V2 assay, Abbott Diagnostics); and HBV surface and core antibodies (AxSYM Core 2.0, Abbott Diagnostics). Participants were considered actively infected by HBV if HBsAg was present and ever infected if HBsAg or anti-HBc or anti-HBs if not vaccinated were detected. 46 HPV genotypes including 13 high-risk (HR) HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) from self-collected anal swab sample were identified using the Luminex microsphere HPV genotyping assay as per the published protocol[31]. We considered a specimen to be positive for HPV if it was positive for any of the 46 genotypes.

Statistical analysis
Laboratory results were double-entered in a Microsoft Excel spreadsheet. The data from the ACASI questionnaire and the laboratory results were analyzed using SAS version 9.3 (SAS, Cary, NC, USA). We examined prevalence (with exact binomial 95% confidence interval [CI]) of STIs stratified by HIV status. Based on previous published reports, for each STI we examined a set of predictors based on demographics (sex, age, ethnic group, region of birth, education level, marital status, annual household income), sexual behaviours (number of lifetime male partners, condomless anal sex with casual partner in the previous 6 months), other health behaviours (smoking, alcohol drink, lifetime injection drug use) and other STIs tested. Wilcoxon-Mann-Whitney test for continuous variables and chi-square test for categorical variables were used for inter-group comparison. Factors with significance level of p<0.10 in the bivariate analysis were included and remained in multivariate logistic regression model with stepwise backwards elimination. Adjusted odds ratio (AOR) and its 95% CI were estimated. Values of p less than 0.05 (two-tailed) were considered statistically significant. Since the focus was the individual null hypotheses of each outcome, the Bonferroni correction for multiple comparisons was not applied, due to concerns over the risk of increased Type II error[32].

Results
Study population
We deliberately oversampled HIV-infected participants, based on prior HIV status, and demographic characteristics are shown in Table 1. The analysis included 294 MSM living with HIV and 148 without, with a median age of 45 years (interquartile range [IQR], 38–50) and 44 years (IQR, 37–50), respectively; the youngest participant was 22 years. Compared to HIV-uninfected participants, MSM living with HIV were more likely to be single and to report ethnicity as other than white, and reported lower levels of education and annual household income.

The majority of subjects identified themselves as gay/homosexual men, although 6.8% (20/294) of participants living with HIV and 5.4% (8/148) without reported being bisexual. MSM living with HIV had more lifetime male partners than HIV-negative men, with 82.0% and 72.8% respectively reporting more than 50 lifetime partners. However, HIV-uninfected men were currently more sexually active and reported more male partners than their counterparts living with HIV, with a median of 5 (IQR, 1–15) and 3 (IQR, 1–8) male partners in the previous 6 months; 62.9% (185/294) of those living with HIV and 66.2% (98/148) of those without reported sex with a casual male partner in the previous 6 months, and the proportion reporting condomless anal sex with casual partners in the previous 6 months was 42.5% (125/294) and 27.0% (40/148), respectively.
Table 1. Demographic characteristics among MSM living with and without HIV in Toronto.

|                        | Living with HIV | Without HIV | p value |
|------------------------|-----------------|-------------|---------|
| Total participants     | 294             | 148         |         |
| Age (years)            |                 |             |         |
| Mean                   | 44.4            | 44.3        | NS      |
| Median (IQR)           | 45 (38–50)      | 44 (37–50)  |         |
| Marital status         |                 |             |         |
| Married/common-law (female) | 2 (0.7%)      | 1 (0.7%)    | 0.0013  |
| Married/common-law (male) | 56 (19.0%)    | 55 (37.4%)  |         |
| Separated/divorced/widowed (female) | 14 (4.8%)  | 6 (4.1%)    |         |
| Separated/divorced/widowed (male) | 41 (13.9%)   | 18 (12.2%)  |         |
| Single                 | 181 (61.6%)     | 67 (45.6%)  |         |
| Education              |                 |             |         |
| Elementary school      | 4 (1.4%)        | 0 (0.0%)    | 0.0001  |
| Secondary school       | 62 (21.1%)      | 11 (7.4%)   |         |
| Some college/university| 79 (26.9%)      | 34 (23.0%)  |         |
| Completed college/university | 117 (39.8%) | 71 (48.0%)  |         |
| Some/completed graduate education | 32 (10.9%) | 32 (21.6%)  |         |
| Annual household income|                 |             |         |
| < $20,000              | 121 (42.6%)     | 29 (20.4%)  | <0.0001 |
| $20,000–$39,999        | 48 (16.9%)      | 15 (10.6%)  |         |
| $40,000–$59,999        | 46 (16.2%)      | 22 (15.5%)  |         |
| $60,000–$79,999        | 17 (6.0%)       | 22 (15.5%)  |         |
| $80,000 +              | 52 (18.3%)      | 54 (38.0%)  |         |
| Region of birth        |                 |             |         |
| Canada                 | 221 (75.2%)     | 113 (76.4%) | NS      |
| United States          | 5 (1.7%)        | 3 (2.1%)    |         |
| Central/South America/Caribbean | 37 (12.6%) | 14 (9.5%)   |         |
| Europe                 | 18 (6.1%)       | 11 (7.4%)   |         |
| Other                  | 11 (4.1%)       | 10 (6.8%)   |         |
| Current immigration status|            |             |         |
| Canadian citizen       | 275 (93.5%)     | 139 (93.9%) | NS      |
| Landed/permanent resident | 13 (4.4%)    | 5 (3.4%)    |         |
| Refugee/refugee claimant | 6 (2.0%)       | 2 (1.4%)    |         |
| Other                  | 0 (0.0%)        | 2 (1.4%)    |         |
| Language 1st learned and still understand | | | |
| English                | 246 (84.8%)     | 126 (86.3%) | NS      |
| French                 | 10 (3.4%)       | 3 (2.1%)    |         |
| Other                  | 34 (11.7%)      | 17 (11.6%)  |         |
| Race/ethnicity         |                 |             |         |
| White                  | 211 (75.1%)     | 119 (82.6%) | 0.011   |
| Black                  | 20 (7.1%)       | 3 (2.1%)    |         |
| Asian                  | 9 (3.2%)        | 10 (6.9%)   |         |
| Latin American         | 14 (5.0%)       | 7 (4.9%)    |         |
| Aboriginal             | 17 (6.0%)       | 1 (0.7%)    |         |
| Mixed                  | 10 (3.6%)       | 4 (2.8%)    |         |

doi:10.1371/journal.pone.0158090.t001
Co-infections

We next assessed the prevalence of bacterial and viral pathogens (Table 2), and examined covariates of reportable infections where prevalence was found to be above 10% in either infected or uninfected MSM participants. 49.4% of MSM living with HIV had serologic evidence of lifetime HBV infection versus 19.1% of those without. Active HBV infection tended to be more common in men living with HIV, although this difference was not statistically significant (2.7% vs. 0.7%). While HBV vaccination was frequent, regardless of HIV status (83.3% and 87.4% for men living with and without HIV, respectively), over half of men living with HIV (103/182) and those without (50/90) had received only one or two of the three recommended doses where data were available. HCV infection was found among 10.4% of MSM living with HIV and 3.4% of those without HIV (p = 0.02); however, this difference was largely due to self-reported IDU (any lifetime IDU). The prevalence of HCV was 36.1% among MSM living with HIV who reported prior use of intravenous drugs (IDU) and 37.5% among HIV-uninfected MSM-IDUs, versus 3.6% in MSM living with HIV who reported no prior IDU and 1.4% among HIV-uninfected MSM without prior IDU.

Syphilis infection (both ever infected and active/current infection) was more prevalent among MSM living with HIV (ever infected, 36.9% vs. 20.4%, p = 0.0007; actively infected, 11.0% vs. 3.4%, p = 0.01, respectively). Urethral chlamydia and gonorrhea were infrequent. CMV infection was very common in both groups, and was detected in nearly all HIV-infected men (98.3%) compared to 80.3% in HIV-uninfected men, p<0.0001. HSV-1 infection was present among 78.5% of MSM living with HIV and 69.4% of those without (p = 0.04) and HSV-2 infection was also more frequent in HIV-infected men (55.9% vs. 38.2%; p = 0.0005). Anal HPV infection (either HR or LR HPV genotypes) was detected in 88.4% of men living with HIV and 77.9% of those without (p = 0.004). The prevalence of any HR HPV genotype infection was 67.6% and 51.7% in MSM living with and without HIV (p = 0.001).

Covariates of viral hepatitis

Among HIV-negative MSM, factors associated with ever having HBV infection in multivariable analysis are shown in Table 3; age was of borderline significance in relation to HBV

---

**Table 2. Prevalence of bacterial and viral pathogens among MSM living with and without HIV in Toronto*.**

| STI                        | Living with HIV | Living without HIV | p value |
|---------------------------|-----------------|--------------------|---------|
|                           | Tested | Positive | Prevalence % (95% CI**) | Tested | Positive | Prevalence % (95% CI**) |         |
| Chlamydia (urethral)      | 290    | 3        | 1.0% (0.2–3.0%)        | 148    | 0        | 0.0% (0.0–2.5%)        | NS      |
| Gonorrhea (urethral)      | 292    | 1        | 0.34% (0.0–1.9%)       | 147    | 0        | 0.0% (0.0–2.5%)        | NS      |
| Syphilis active           | 290    | 32       | 11.0% (7.7–15.2%)      | 147    | 5        | 3.4% (1.1–7.8%)        | 0.012   |
| Syphilis ever             | 290    | 107      | 36.9% (31.3–42.7%)     | 147    | 30       | 20.4% (14.2–27.8%)     | 0.0007  |
| HSV-1                     | 288    | 226      | 78.5% (73.3–83.1%)     | 144    | 100      | 69.4% (61.2–76.8%)     | 0.040   |
| HSV-2                     | 288    | 161      | 55.9% (50.0–61.7%)     | 144    | 55       | 38.2% (30.2–46.7%)     | 0.0005  |
| Cytomegalovirus           | 292    | 287      | 98.3% (96.1–99.4%)     | 147    | 118      | 80.3% (72.9–86.4%)     | <0.0001 |
| High risk HPV, anal       | 284    | 192      | 67.6% (61.8–73.0%)     | 145    | 75       | 51.7% (43.3–60.1%)     | 0.0013  |
| HCV                       | 289    | 30       | 10.4% (7.1–14.5%)      | 148    | 5        | 3.4% (1.1–7.7%)        | 0.018   |
| HBV infected †            | 291    | 8        | 2.7% (1.2–5.3%)        | 141    | 1        | 0.7% (0.0–3.9%)        | NS      |
| HBV ever ‡                | 291    | 144      | 49.4% (43.6–55.4%)     | 141    | 27       | 19.1% (13.0–26.6%)     | <0.0001 |

* The total number of participants tested for individual STIs varied due to insufficient specimens or invalid laboratory results

** 95% exact binomial confidence interval

† Infected with HBV: HBsAg, with or without other HBV markers

‡ Ever infected with HBV: HBsAg, anti-HBc, or anti-HBs if not vaccinated for HBV

---

doi:10.1371/journal.pone.0158090.t002
Table 3. Correlates of hepatitis B virus infection among MSM in Toronto.

| Participants living without HIV** | HBV infection | Non-infection | % HBV infection | p value | Adjusted odds ratio *(95%CI) | p value |
|----------------------------------|---------------|---------------|-----------------|---------|-----------------------------|---------|
| **Age (years)**                  |               |               |                 |         |                             |         |
| Mean                             | 50.4          | 43.1          | 0.0009          | 1.60 (0.95–2.70)† | 0.079 |
| Median (IQR)                     | 51.0 (42–55)  | 44.0 (35–49)  |                 |         |                             |         |
| **Education**                    |               |               |                 |         |                             |         |
| Some college/university or less  | 13            | 29            | 31.0%           | 0.037   |                             |         |
| Completed college/university or high school | 14            | 85            | 14.1%           |         |                             |         |
| **Annual household income**      |               |               |                 |         |                             |         |
| Less than $50,000                | 17            | 36            | 32.1%           | 0.0093  |                             |         |
| $50,000 or more                  | 10            | 72            | 12.2%           |         |                             |         |
| **Number of lifetime male partners** |           |               |                 |         |                             |         |
| 50+                              | 24            | 80            | 23.1%           | 0.091   | 18.3 (1.86–180.4)           | 0.013   |
| <50                              | 3             | 33            | 8.3%            | 1.0     |                             |         |
| **Injection drug use (lifetime)**|               |               |                 |         |                             |         |
| Yes                              | 4             | 4             | 50.0%           | 0.045   |                             |         |
| No                               | 23            | 109           | 17.4%           |         |                             |         |
| **Cytomegalovirus infection**    |               |               |                 |         |                             |         |
| Yes                              | 26            | 89            | 22.6%           | 0.047   |                             |         |
| No                               | 1             | 24            | 4.0%            |         |                             |         |
| **Syphilis**                     |               |               |                 |         |                             |         |
| Yes                              | 11            | 19            | 36.7%           | 0.009   |                             |         |
| No                               | 15            | 95            | 13.6%           |         |                             |         |
| **HBV vaccination**              |               |               |                 |         |                             |         |
| Yes                              | 14            | 104           | 11.9%           | 1.0     |                             |         |
| No                               | 10            | 7             | 58.8%           | <0.0001 | 3.45 (1.65–7.19)           | 0.0010  |
| **Participants living with HIV*** |               |               |                 |         |                             |         |
| **Age (years)**                  |               |               |                 |         |                             |         |
| Mean                             | 47.3          | 41.5          | <0.0001         | 1.90 (1.35–2.67)† | 0.0003 |
| Median (IQR)                     | 47.0 (43–52)  | 42.0 (34–47)  |                 |         |                             |         |
| **Education**                    |               |               |                 |         |                             |         |
| Some college/university or less  | 80            | 64            | 55.6%           | 0.053   |                             |         |
| Completed college/university or high school | 64            | 83            | 43.5%           |         |                             |         |
| **Number of lifetime male partners** |           |               |                 |         |                             |         |
| 50+                              | 121           | 113           | 51.7%           | 0.11    |                             |         |
| <50                              | 20            | 32            | 38.5%           |         |                             |         |
| **Smoking**                      |               |               |                 |         |                             |         |
| Ever                             | 114           | 92            | 55.3%           | 0.003   | 2.30 (1.21–4.39)           | 0.012   |
| Never                            | 30            | 55            | 35.3%           |         |                             |         |
| **Alcohol drinking in the previous 6 months** | 27            | 13            | 67.5%           | 0.022   | 2.86 (1.20–6.82)           | 0.018   |
| Yes                              | 117           | 134           | 46.6%           | 1.0     |                             |         |
| No                               | 27            | 13            | 67.5%           | 0.022   | 2.86 (1.20–6.82)           | 0.018   |
| HSV-2 infection                  |               |               |                 |         |                             |         |
| Yes                              | 94            | 66            | 58.8%           | 0.0006  | 1.86 (1.03–3.35)           | 0.037   |
| No                               | 47            | 78            | 37.6%           | 1.0     |                             |         |
| Syphilis                         |               |               |                 |         |                             |         |
| Yes                              | 64            | 42            | 60.4%           | 0.007   | 1.92 (1.04–3.56)           | 0.039   |
| No                               | 78            | 103           | 43.1%           | 1.0     |                             |         |

*(Continued)*
infection, while the number of lifetime partners and HBV vaccination remained significantly associated with HBV status. Among MSM living with HIV, prior HBV infection was associated with older age, ever smoking, alcohol abstinence, HSV-2, syphilis infection and HBV vaccination in both bivariate and multivariate analyses (Table 3). Among subjects with available data, we observed a dose-response effect of the number of doses of HBV vaccine on ever HBV infection regardless of HIV infection status. Among men living with HIV the proportions of ever HBV infection were 88.9% for unvaccinated participants, 58.3% for those with one dose, 39.2% with two doses, and 25.3% among fully-vaccinated men (p for trend < 0.0001). Among HIV-uninfected men the proportions were 58.8%, 0.0%, 11.6% and 5.0% (p for trend < 0.0001).

Lifetime IDU was strongly associated with HCV infection among HIV-uninfected MSM (37.5% vs. 1.4%, p = 0.0010); no associations were seen with sexual behaviours or STIs. Table 4 summarizes the results of the analysis of the covariates of HCV infection among MSM living with HIV. Here, HSV-2 and syphilis infection were associated with HCV infection in bivariate analysis. Age, current smoking, alcohol abstinence in the previous 6 months, IDU and HBV infection remained significantly related to HCV infection in the multivariate analysis.

Among HBV-infected men living with HIV, 31.6% of were aware of their HBV infection status, and the inverse association between alcohol drinking and HBV infection persisted when these participants were excluded, implying that it was not predicated on an awareness of HBV infection. The great majority (93%) of HCV-infected men living with HCV were aware of their HCV infection, and so a similar analysis was not feasible.

### Covariates of syphilis infection

Among HIV-uninfected MSM, the lifetime prevalence of syphilis infection (“ever syphilis”) increased with increasing age (20–29 years, 0.0%; 30–54, 16.8%, and 55+, 45.5%); this was not the case among MSM living with HIV. We then assessed the correlates of ever having syphilis infection by HIV status (see Table 5). Condomless anal sex with casual partners in the previous 6 months was associated with ever syphilis regardless of HIV infection status, but in multivariate analysis, remained significant only among men living with HIV. In bivariate analysis, condomless oral sex with a HIV-infected partner (either casual or regular partner) in the previous 6 months was related to syphilis infection for both MSM living with and without HIV (36.7% vs. 17.1%, and 44.7% vs. 28.2%, respectively), but significance was lost in multivariate analysis.

---

Table 3. (Continued)

| Covariate                  | Hepatitis B virus infection | Non-infection | % Hepatitis B virus infection | p value | Adjusted odds ratio (95%CI) | p value |
|----------------------------|----------------------------|---------------|-----------------------------|---------|-----------------------------|---------|
| Hepatitis C virus infection| Yes                        | 20            | 10                          | 66.7%   | 0.069                       |         |
|                            | No                         | 121           | 135                         | 47.3%   |                             |         |
| HBV vaccination            | No                         | 40            | 5                           | 88.9%   | <0.0001                     | 2.87 (1.71–4.81) | <0.0001 |
|                            | Yes                        | 88            | 136                         | 39.3%   | 1.0                         |         |

* Logistic regression with backward elimination, p<0.10 stay in the model, initially included all variables listed in the table
**125 HIV-negative MSM with all data
***250 HIV-positive MSM with all data
† Adjusted odds ratio in 10 years of age increase

doi:10.1371/journal.pone.0158090.t003
Discussion

HIV disproportionately affects the MSM community in both developed and less-developed settings[1, 33, 34], and the presence of common STIs can enhance both HIV transmission[12, 35, 36] and progression[37]. To our knowledge, this study represents the most comprehensive assessment to date of viral and bacterial STIs in MSM in Canada, where the estimated HIV prevalence in the community exceeds 15% and HIV incidence remains high. Syphilis (current or ever) and viral STIs (including HSV-2, CMV, HPV, HBV and HCV) were very common in this clinic-based MSM population, and were consistently more frequent among men living with HIV, while urethral gonorrhea and chlamydia were relatively infrequent in all participants.

HCV is most efficiently transmitted through percutaneous route and persons who inject drugs are at greatest risk of infection. In our study sample, HCV infection was highly associated with lifetime (ever) IDU regardless of HIV infection status. The prevalence of HCV was 36.2% among IDU and 2.7% among non-IDUs, 71% of the HCV infections observed were among MSM-IDUs. Although the role of sexual transmission in HCV infection dynamics is controversial[38], a high prevalence of HCV has been observed in MSM who are infected by HIV and who do not report IDU. Among men reporting no prior IDU, the prevalence of HCV was 3.6% among MSM living with HIV and 1.4% among those living without HIV. Our results are in

|                  | HCV infection | Non-infection | % HCV infection | p value | Adjusted odds ratio* (95%CI) | p value |
|------------------|---------------|---------------|-----------------|---------|-----------------------------|---------|
| Age (years)      |               |               |                 |         |                             |         |
| Mean             | 46.7          | 44.1          | 0.11            | 1.97 (1.02–3.78)† | 0.043            |
| Median (IQR)     | 47.0 (45–52)  | 45.0 (38–50)  |                 |         |                             |         |
| Current smoking  |               |               |                 |         |                             |         |
| Yes              | 18            | 94            | 16.1%           | 0.020   | 3.9 (1.33–11.42)            | 0.013   |
| No               | 12            | 165           | 6.8%            | 1.0     |                             |         |
| Alcohol drinking in the previous 6 months | | | | | | |
| No               | 10            | 30            | 25.0%           | 0.0032  | 5.83 (1.72–19.71)           | 0.0046  |
| Yes              | 20            | 229           | 8.0%            | 1.0     |                             |         |
| Injection drug use (lifetime)2 | | | | | | |
| Yes              | 22            | 39            | 36.1%           | <0.0001 | 49.4 (13.7–178.4)           | <0.0001 |
| No               | 8             | 217           | 3.6%            | 1.0     |                             |         |
| HSV-2 infection  |               |               |                 |         |                             |         |
| Yes              | 21            | 138           | 13.2%           | 0.056   |                             |         |
| No               | 7             | 117           | 5.6%            | 1.0     |                             |         |
| Syphilis         |               |               |                 |         |                             |         |
| Yes              | 17            | 90            | 15.9%           | 0.023   |                             |         |
| No               | 12            | 166           | 6.7%            | 1.0     |                             |         |
| HBV infection    |               |               |                 |         |                             |         |
| Yes              | 20            | 121           | 14.2%           | 0.069   | 3.19 (1.06–9.55)           | 0.039   |
| No               | 10            | 135           | 6.9%            | 1.0     |                             |         |

* Logistic regression with backward elimination, p<0.10 stay in the model, initially included all variables listed in the table, among 272 HIV-positive MSM with all data

† Adjusted odds ratio in 10 years of age increase

Note: other variables examined but not significant in the univariate analysis: education, annual household income, region of birth, marital status, race/ethnicity, number of lifetime male partners, unprotected anal sex with casual partner in the previous 6 months, cytomegalovirus and HPV infection

doi:10.1371/journal.pone.0158090.t004
Table 5. Correlates of ever syphilis infection among MSM in Toronto.

| Participants living without HIV** | Syphilis infection | Non-infection | % Syphilis infection | p value | Adjusted odds ratio* (95%CI) | p value |
|-----------------------------------|--------------------|---------------|----------------------|---------|-----------------------------|---------|
| **Age (years)**                   |                    |               |                      |         |                             |         |
| Mean                              | 49.7               | 42.7          | 0.0018               | 2.61 (1.45–4.68)† | 0.0013 |
| Median (IQR)                      | 49.0 (42–58)       | 43.5 (35–49)  |                      |         |                             |         |
| **Household income**              |                    |               |                      |         |                             |         |
| Less than $20,000                 | 11                 | 18            | 0.019                | 6.41 (1.84–22.40) | 0.0036 |
| $20,000 or more                   | 18                 | 94            | 1.0                  |         |                             |         |
| **UAI with casual partners in past 6 months** |                    |               |                      |         |                             |         |
| Yes                               | 12                 | 28            | 0.11                 |         |                             |         |
| No                                | 18                 | 89            | 1.0                  |         |                             |         |
| **Injection drug use**            |                    |               |                      |         |                             |         |
| Yes                               | 6                  | 2             | 0.0008               | 51.78 (3.65–734.8) | 0.0035 |
| No                                | 23                 | 115           | 1.0                  |         |                             |         |
| **HSV-2 infection**               |                    |               |                      |         |                             |         |
| Yes                               | 18                 | 36            | 0.0089               | 1.0     |                             |         |
| No                                | 12                 | 77            | 1.0                  |         |                             |         |
| **Cytomegalovirus infection**     |                    |               |                      |         |                             |         |
| Yes                               | 29                 | 88            | 0.022                | 1.0     |                             |         |
| No                                | 1                  | 28            | 3.4%                 |         |                             |         |
| **HBV infection**                 |                    |               |                      |         |                             |         |
| Yes                               | 11                 | 15            | 0.0090               |         |                             |         |
| No                                | 19                 | 95            | 1.0                  |         |                             |         |
| **Anal HPV infection**            |                    |               |                      |         |                             |         |
| Yes                               | 28                 | 85            | 0.048                | 10.02 (1.05–95.48) | 0.045 |
| No                                | 2                  | 29            | 6.5%                 |         |                             |         |
| **Participants living with HIV***  |                    |               |                      |         |                             |         |
| **Region of birth**               |                    |               |                      |         |                             |         |
| Canada/United States              | 74                 | 148           | 0.026                | 0.41 (0.20–0.84) | 0.014 |
| Other                             | 33                 | 34            | 1.0                  |         |                             |         |
| **Ethnicity**                     |                    |               |                      |         |                             |         |
| White                             | 70                 | 137           | 0.064                |         |                             |         |
| Other                             | 33                 | 37            | 47.1%                |         |                             |         |
| **Number of lifetime male partners** |                    |               |                      |         |                             |         |
| 50+                               | 94                 | 139           | 0.003                | 2.56 (1.04–6.34) | 0.042 |
| <50                               | 9                  | 43            | 1.0                  |         |                             |         |
| **UAI with casual partners in past 6 months** |                    |               |                      |         |                             |         |
| Yes                               | 59                 | 63            | 0.0009               | 1.89 (1.06–3.35) | 0.030 |
| No                                | 48                 | 120           | 1.0                  |         |                             |         |
| **Alcohol drinking in the previous 6 months** |                    |               |                      |         |                             |         |
| No                                | 21                 | 18            | 0.029                |         |                             |         |
| Yes                               | 86                 | 165           | 34.3%                |         |                             |         |
| **Injection drug use**            |                    |               |                      |         |                             |         |
| Yes                               | 35                 | 25            | 0.0002               | 3.18 (1.58–6.38) | 0.0012 |
| No                                | 70                 | 157           | 1.0                  |         |                             |         |
| **HSV-2 infection**               |                    |               |                      |         |                             |         |
| Yes                               | 67                 | 91            | 0.032                |         |                             |         |
| No                                | 37                 | 89            | 0.032                |         |                             |         |

(Continued)
keeping with studies that described a higher prevalence of HCV among MSM living with HIV who lack risk factors for percutaneous exposure[30, 39, 40]. Specifically, the prevalence of HCV among MSM living with HIV and who reported no prior IDU was 3.6%, which was higher than the estimated 1.1% prevalence in the overall male population in Toronto[39]. We did not observe an association between HCV prevalence and sexual practices, perhaps because sexual behaviour during the previous 6 months differed from that at the time of HCV infection. However, prospective cohort and case-control studies have found that condomless receptive anal intercourse was linked to the risk of sexually acquired HCV infection among HIV-infected MSM[30, 41–43]. Although it can be difficult to control for additional avenues for percutaneous blood exposure during condomless sex[44], biologic evidence supports the possibility of sexual transmission, as HCV RNA has been detected in semen and other body fluids[45, 46]. The lower HCV prevalence among HIV-negative MSM who reported no IDU history (1.4%) was comparable to the general population and similar to previous studies[47, 48].

The proportion of participants with prior HBV vaccination was high in both MSM living with and without HIV, but HBV infection was not uncommon and was associated with older age and more lifetime male sexual partners, suggesting that these persons may have been infected prior to being vaccinated. Therefore, efforts should be made to reinforce timely HBV vaccination among MSM.

Our findings regarding the prevalence of ever having had syphilis are consistent with, and extend, previous findings. In particular, Burchell and colleagues[49] found that the prevalence of prior syphilis was 30.3% among Ontario MSM living with HIV in 2009; this was similar to the 36.9% observed in our study and much higher than the 5.4% prevalence they report in non-MSM men living with HIV. However, their study was unable to assess HIV-negative MSM from the same community, and the 20.4% prevalence of prior syphilis infection we observed in the latter group is still over ten-fold higher than the prevalence in the general Ontario population[49]. Oral sex is associated with transmission of syphilis. A study in Chicago, USA showed that 20% primary and secondary syphilis cases among MSM during 2000–2002 were attributed to oral sex[50]. Our study also found that syphilis was more common among MSM with condomless oral sex, suggesting that the role of oral sex in transmission should be emphasized in syphilis education programs.

While urethral gonorrhea and chlamydia were infrequent in our study, this may relate to the relatively advanced age of participants and to our lack of rectal and pharyngeal screening.

**Table 5. (Continued)**

|                  | Syphilis infection | Non-infection | % Syphilis infection | p value | Adjusted odds ratio* (95%CI) | p value |
|------------------|-------------------|--------------|---------------------|---------|-----------------------------|---------|
| HCV infection    |                   |              |                     |         |                             |         |
| Yes              | 17                | 12           | 58.6%               | 0.023   |                             |         |
| No               | 90                | 166          | 35.2%               |         |                             |         |
| HBV infection    |                   |              |                     |         |                             |         |
| Yes              | 64                | 78           | 45.1%               | 0.0068  | 2.67 (1.48–4.79)            | 0.0011  |
| No               | 42                | 103          | 29.0%               |         | 1.0                         |         |
| Anal HPV infection |                 |              |                     |         |                             |         |
| Yes              | 100               | 148          | 40.3%               | 0.0089  | 4.11 (1.26–13.36)           | 0.019   |
| No               | 5                 | 28           | 15.2%               |         | 1.0                         |         |

* Logistic regression with backward elimination, p<0.10 stay in the model.
** 125 HIV-negative MSM with all data
*** 246 HIV-positive MSM with all data.
† Adjusted odds ratio in 10 years of age increase

doi:10.1371/journal.pone.0158090.t005
Indeed, a retrospective study in San Francisco found that most asymptomatic chlamydia (77%) and gonorrhea (95%) infections would have been missed in the absence of rectal and pharyngeal screening\(^{[51]}\). Therefore, rectal and pharyngeal screening in MSM would be beneficial in future studies\(^{[52]}\).

We found that the prevalence of HSV-2 (38%) and anal high-risk HPV (52%), both of which may enhance HIV susceptibility\(^{[9–11, 13]}\), were much higher among HIV-negative MSM than previously described in the general population or other MSM communities\(^{[14, 18, 31, 32, 50, 51, 53, 54]}\). A study among predominantly heterosexual men from two STI clinics in Alberta, Canada found an HSV-2 prevalence of 19\(^{\%}\)\(^{[54]}\), and the age-standardized seroprevalence of HSV-2 in the general male population aged 15 to 44 years old from Ontario, Canada was 8.6\(^{\%}\)\(^{[53]}\). Furthermore, a study of anal high-risk HPV infection in MSM from the United States and other countries in the region found a prevalence of 27\(^{\%}\) in MSM and 6.8\(^{\%}\) in heterosexual men\(^{[6]}\), both considerably lower than the 51.7\(^{\%}\) that we observed in HIV-negative MSM. While HPV may impact HIV transmission, the clearest implications relate to the need for HPV vaccination and anal cancer prevention programs in men practicing receptive anal sex, where the prevalence of anal cancer and anal intraepithelial neoplasia are dramatically increased\(^{[10]}\).

Several caveats should be noted regarding this study. The nature of this cross-sectional study does not allow us to determine whether HSV-2, HPV, HBV and HCV infection were acquired before or after HIV infection, or to infer causality in the co-infection relationships that we observed. Sexual behaviours were assessed through self-report, and there may be inaccuracies due to recall bias. Also, sexual behaviours collected in the previous 6 months of the survey may not represent those at time of HIV acquisition, particularly for persistent pathogens such as herpesvirus. While prior HBV infection was common among persons who reported HBV vaccination, our study design cannot determine whether this occurred before vaccination or represented vaccine failure.

Our study recruitment was clinic-based, and so it not clear to what extent these results can be extrapolated to MSM from Toronto who are not in medical care. The Maple Leaf Medical Clinic provides care for over 10,000 MSM, and as such is the largest provider of MSM care in Toronto. However, it is likely that men in regular care at this site differ in several ways to those not in care, or in care at less community-focused clinics. Further selection bias may also apply to participant uptake within the clinic, such that men who participated may have differed from non-participants in unknown ways. We do not believe that these potential biases would lead to an over-estimation of STI prevalence among participants, since testing and treatment for most study STIs is already available free of charge within the clinic (exceptions being screening for asymptomatic HSV1/2 and HPV); if anything, we suspect that the STI prevalence among sexually active MSM from the community who are not in care would be higher than those that we observed. Formal data regarding participation rates were not collected, but clinic staff informally estimated participation to have been approximately 95\(^{\%}\) among HIV+ men and 70\(^{\%}\) among HIV-uninfected men [Loutfy M, personal communication]. This differential participation was due in part to greater familiarity of infected men with research, as the clinic participates in numerous HIV clinical trials.

In summary, we found that several sexually transmitted co-infections were very common among MSM in Toronto living both with and without HIV, particularly HPV, several herpesviruses, viral hepatitis and syphilis. The association of these STIs with enhanced HIV transmission and with adverse health outcomes in their own right emphasizes the critical need for a community-specific prevention strategy. Enhanced STI screening, HBV and HPV vaccine-based prevention and education programs need to be implemented in this high-risk community. In addition, novel strategies currently under study in MSM communities may be useful in...
the future, including presumptive STI treatment and/or models of self-administered rectal and pharyngeal screening that minimize the need for health care encounters.

Acknowledgments

We thank the study participants, Jennifer Robinette and physicians at Maple Leaf Medical Clinic, staff at laboratories for diagnostic testing (Rupert Kaul laboratory; Department of Pathology, UHN; Toronto Medical Laboratories, Mt. Sinai Hospital; Toronto Public Health Laboratory; and Public Health Ontario). The study was funded by an Emerging Team Grant from the Canadian Institutes of Health Research, Canada (Grant number HET-85518). Dr. Robert Remis passed away before the submission of the final version of this manuscript; Dr. Rupert Kaul accepts responsibility for the integrity and validity of the data collected and analyzed.

Author Contributions

Conceived and designed the experiments: RR ML MK WT RK. Performed the experiments: RR ML SH AR RH TG JB GS TR. Analyzed the data: RR JL. Contributed reagents/materials/analysis tools: AR. Wrote the paper: RR JL WT ML RK.

References

1. Estimates of HIV prevalence and incidence in Canada, 2011. Available at http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/assets/pdf/estimat2011-eng.pdf. In: Edited by Canada PHAo: Public Health Agency of Canada; 2013.

2. Remis RS, Swantee C, Liu J. Report on HIV/AIDS in Ontario 2009. Available at: http://www.ohem.utoronto.ca/doc/HERO2009_report_final.pdf. In: Ontario Ministry of Health and Long-Term Care; 2012.

3. Drew WL, Mintz L, Miner RC, Sands M, Ketterer B. Prevalence of Cytomegalovirus-Infection in Homosexual Men. Journal of Infectious Diseases 1981, 143:188–192. PMID: 6260871

4. Xu FJ, Sternberg MR, Markowitz LE. Men Who Have Sex With Men in the United States: Demographic and Behavioral Characteristics and Prevalence of HIV and HSV-2 Infection Results from National Health and Nutrition Examination Survey 2001–2006. Sexually Transmitted Diseases 2010, 37:399–405. doi: 10.1097/OLQ.0b013e3181ce122b PMID: 20473245

5. Gilbert M, Kwag M, Mei W, Rank C, Kropp R, Severini A, et al. Feasibility of Incorporating Self-Collected Rectal Swabs Into a Community Venue-Based Survey to Measure the Prevalence of HPV Infection in Men Who Have Sex With Men. Sexually Transmitted Diseases 2011, 38:964–969. doi: 10.1097/OLQ.0b013e318222899d PMID: 21934574

6. Nyitray AG, da Silva RJC, Baggio ML, Lu BB, Smith D, Abrahamsen M, et al. Age-Specific Prevalence of and Risk Factors for Anal Human Papillomavirus (HPV) among Men Who Have Sex with Women and Men Who Have Sex with Men: The HPV in Men (HIM) Study. Journal of Infectious Diseases 2011, 203:49–57. doi: 10.1093/infdis/jiq021 PMID: 21148496

7. Pathela P, Braunstein SL, Schillinger JA, Shepard C, Sweeney M, Blank S. Men Who Have Sex With Men Have a 140-Fold Higher Risk for Newly Diagnosed HIV and Syphilis Compared With Heterosexual Men in New York City. Jids-Journal of Acquired Immune Deficiency Syndromes 2011, 58:408–416.

8. Wolitski RJ, Fenton KA. Sexual Health, HIV, and Sexually Transmitted Infections among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States. Behav and Health 2011, 15:S9–S17. doi: 10.1007/s10461-011-9901-6 PMID: 21331797

9. Butler DM, Smith DM, Cachay ER, Hightower GK, Nugent CT, Richman DD, et al. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS. 2008, 22:1667–1671. doi: 10.1097/QAD.0b013e32830b6ed8 PMID: 18670228

10. Chin-Hong PV, Husnik M, Cranston RD, Colfax G, Buchbinder S, Da Costa M, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009, 23:1135–1142. doi: 10.1097/QAD.0b013e32832b4449 PMID: 19390418

11. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20:73–83. PMID: 16327322
12. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004, 2:33–42. PMID: 15035007

13. Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 2012, 26:2211–2222. doi: 10.1097/QAD.0b013e3283584908 PMID: 22874522

14. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012, 9:139–147. doi: 10.1007/s11904-012-0118-8 PMID: 22528766

15. Rebbapragada A, Kaul R. More than their sum in your parts: the mechanisms that underpin the mutually advantageous relationship between HIV and sexually transmitted infections. Drug Discovery Today: Disease Mechanisms 2007, 4:237–246.

16. Bohl DD, Katz KA, Bernstein K, Wong E, Raymond HF, Klausner JD, et al. Prevalence and Correlates of Herpes Simplex Virus Type-2 Infection Among Men Who Have Sex With Men, San Francisco, 2008. Sexually Transmitted Diseases 2011, 38:617–621. doi: 10.1097/OLQ.0b013e31820a8c10 PMID: 21278625

17. Hill C, McKinney E, Lowndes CM, Munro H, Murphy G, Parry JV, et al. Epidemiology of herpes simplex virus types 2 and 1 amongst men who have sex with men attending sexual health clinics in England and Wales: implications for HIV prevention and management. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19418. In: Eurosurveillance; 2009.

18. Wiley DJ, Li XH, Hsu H, Seaberg EC, Cranston RD, Young S, et al. Factors Affecting the Prevalence of Strongly and Weakly Carcinogenic and Lower-Risk Human Papillomaviruses in Anal Specimens in a Cohort of Men Who Have Sex with Men (MSM). Plos One 2013, 8.

19. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. Journal of Hepatology 2006, 44:S6–S9. PMID: 16352363

20. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921–1926. PMID: 12493258

21. Rockstroh JK. Influence of viral hepatitis on HIV infection. Journal of Hepatology 2006, 44:S25–S27. PMID: 16338020

22. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800–1805. PMID: 1117912

23. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sympsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009, 48:1763–1771. doi: 10.1086/599110 PMID: 19435436

24. van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chenes G, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013, 144:751–760 e752. doi: 10.1053/j.gastro.2012.12.026 PMID: 23266560

25. Wang H, Li Y, Zhang C, Han Y, Zhang X, Zhu T, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS 2012, 26:1755–1763. PMID: 22614885

26. Andonov A, Butler G, Ling R, Prichard LM, Baril JG, Gale-Rowe M, et al. Primary care management of hepatitis B—Quick Reference (HBV-QR). Available at: http://www.phac-aspc.gc.ca/publicat/hep/hbv-vhb/index-eng.php. In. Edited by Canada PHAo; 2013.

27. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333–1342. doi: 10.1002/hep.26141 PMID: 23172780

28. van de Laar TJW, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010, 24:1799–1812. doi: 10.1097/QAD.0b013e32833e11a5 PMID: 20601854

29. van de Laar TJW, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. Journal of Infectious Diseases 2007, 196:230–238. PMID: 17570110

30. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. Aids 2007, 21:983–991. PMID: 17457092

31. Zubach V, Smart G, Ratnam S, Severini A. Novel Microsphere-Based Method for Detection and Typing of 46 Mucosal Human Papillomavirus Types. Journal of Clinical Microbiology 2012, 50:460–464. doi: 10.1128/JCM.06090-11 PMID: 22116162
32. Perneger TV. What's wrong with Bonferroni adjustments. British Medical Journal 1998, 316:1236–1238. PMID: 9553006
33. Beyrer C, Baral SD, van Griensven F, Goodreau SM, Charuvalaetsk S, Wirtz AL, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012, 380:367–377. doi: 10.1016/S0140-6736(12)60821-6 PMID: 22819660
34. Geibel S, Tun W, Tapsoba P, Kellerman S. HIV vulnerability of men who have sex with men in developing countries: Horizons studies, 2001–2008. Public Health Rep 2010, 125:316–324. PMID: 20297760
35. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009, 9:118–129. doi: 10.1016/S1473-3099(09)70021-0 PMID: 19179227
36. McKinnon LR, Izulla P, Nagelkerke N, Munyao J, Wanjiru T, Shaw SY, et al. Risk factors for HIV acquisition in a prospective Nairobi-based female sex worker cohort. AIDS Behav 2015.
37. Chun HM, Carpenter RJ, Macalino GE, Crum-Cianflone NF. The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. J Sex Transm Dis 2013, 2013:176459. doi: 10.1155/2013/176459 PMID: 26316953
38. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010, 24:1799–1812. doi: 10.1097/QAD.0b013e32833c11a5 PMID: 20601854
39. Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002–2006: is this an outbreak? Sex Transm Infect 2008, 84:111–115.
40. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007, 196:230–238. PMID: 17570110
41. Centers for Disease C, Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005–2010. MMWR Morb Mortal Wkly Rep 2011, 60:945–950. PMID: 21775948
42. Rauch A, Rickenbach M, Weber R, Hirschez B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005, 41:395–402. PMID: 16007539
43. Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984–2011. Clin Infect Dis 2013, 57:77–84. doi: 10.1093/cid/cit197 PMID: 23532480
44. Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, Krznaric I, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany—a case-control study. PLoS One 2011, 6:e17781. doi: 10.1371/journal.pone.0017781 PMID: 21408083
45. Briat A, Dulouest E, Gailmand J, Fontaine H, Chaix ML, Letur-Konirsch H, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 2005, 19:1827–1832. doi: 10.1097/01.aids.0000193526.07781.5a PMID: 16227790
46. Leruez-Ville M, Kunstmann JM, De Almeida M, Rouziouix C, Chaix ML, Detection of hepatitis C virus in the semen of infected men. Lancet 2000, 356:42–43. PMID: 10892766
47. Jin F, Prestage GP, Matthews G, Zablotska I, Rawstone P, Kippax SC, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010, 86:25–28. doi: 10.1136/sti.2009.038182 PMID: 20640834
48. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009, 23:1–7. doi: 10.1097/QAD.0b013e32832e5631 PMID: 19542864
49. Burchell AN, Allen VG, Moravan V, Gardner S, Raboud J, Tan DH, et al. Patterns of syphilis testing in a large cohort of HIV patients in Ontario, Canada, 2000–2009. BMC Infect Dis 2013, 13:246.
50. Centers for Disease C, Prevention. Transmission of primary and secondary syphilis by oral sex—Chicago, Illinois, 1998–2002. MMWR Morb Mortal Wkly Rep 2004, 53:966–968. PMID: 15496825
51. Marcus JL, Bernstein KT, Kohn RP, Liska S, Philip SS. Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis 2011, 38:922–924. doi: 10.1097/OLQ.0b013e31822a2b2e PMID: 21934565
52. Chesson HW, Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK. The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection. Sex Transm Dis 2013, 40:366–371. doi: 10.1097/OLQ.0b013e318284e544 PMID: 23588125
53. Howard M, Sellors JW, Jang D, Robinson NJ, Faron M, Kaczorowski J, et al. Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada. J Clin Microbiol 2003, 41:84–89. PMID: 12517830

54. Singh AE, Romanowski B, Wong T, Gourishankar S, Myziuk L, Fenton J, et al. Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics. Sex Transm Dis 2005, 32:95–100. PMID: 15668615